<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two HIV patients with Epstein-Barr virus (EBV)-associated B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> of high grade <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> enjoyed prolonged remission after therapy with COPBLAM and the <z:chebi fb="1" ids="22587">antiviral agent</z:chebi> <z:chebi fb="4" ids="2453">Acyclovir</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>After 3, respectively 5 cycles of treatment, the patients (stage C3 according to CDC) responded to the administered drugs by achieving complete remission </plain></SENT>
<SENT sid="2" pm="."><plain>Under maintenance therapy with <z:chebi fb="4" ids="2453">Acyclovir</z:chebi> for 32, respectively 31 months, both patients still remain free of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> as of today </plain></SENT>
</text></document>